Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(10)

• #EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity
  MILAN — Boehringer Ingelheim’s lead obesity candidate prompted weight loss of up to 9.8% in a late-stage trial in patients with both obesity and type 2 diabetes, according to data presented Thursda…
  endpoints · 2h ago
• Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
  EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…
  biospace · 20h ago
• #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
  MILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination del…
  endpoints · 20h ago
• STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
  An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
  stat · 20h ago
• Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
  Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive p…
  biospace · 21h ago
• Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
  Eli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrut…
  fiercebiotech · 22h ago
• Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
  Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin analog delivered the highest weight loss—9.8%—at Week 28.
  fiercebiotech · 1d ago
• Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
  Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the top dose of the triple-G drug candidate lost at least 25% of their body we…
  fiercebiotech · 1d ago
• #EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
  MILAN — Eli Lilly said Tuesday that its triple agonist retatrutide helped patients with both obesity and type 2 diabetes lose up to 18.8% of their weight after about a year and a half. Also, 60% ...
  endpoints · 1d ago
• Roche cuts muscle-sparing obesity drug after mid-stage disappointment
  Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…
  biospace · 1d ago